Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

INZY

Inozyme Pharma Inc

Dec 12 • 11:26AM ET

3.14

Dollar change +0.18
Percentage change 6.25	%

Healthcare • Biotechnology • USA • NASD

Peers: CARA RIGL KYMR MRNS FATE ABEO RCUS PULM SLNO ANIX

| Held by: VTI IWM VXF IWN VTWO IWC DFAS AVSC DFAC VTWV

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.55	Insider Own	31.52%	Shs Outstand	64.18M	Perf Week	26.81%
Market Cap	202.03M	Forward P/E	-	EPS next Y	-1.60	Insider Trans	0.00%	Shs Float	43.99M	Perf Month	-16.36%
Income	-96.49M	PEG	-	EPS next Q	-0.41	Inst Own	65.07%	Short Float	7.75%	Perf Quarter	-47.58%
Sales	0.00M	P/S	-	EPS this Y	-16.72%	Inst Trans	2.30%	Short Ratio	8.06	Perf Half Y	-35.15%
Book/sh	1.29	P/B	2.44	EPS next Y	-0.06%	ROA	-55.29%	Short Interest	3.41M	Perf Year	-14.54%
Cash/sh	2.05	P/C	1.54	EPS next 5Y	13.10%	ROE	-79.42%	52W Range	2.38 - 7.80	Perf YTD	-26.17%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-35.73%	ROI	-77.18%	52W High	-59.65%	Beta	1.37
Dividend TTM	-	Quick Ratio	7.68	Sales past 5Y	0.00%	Gross Margin	-	52W Low	31.87%	ATR (14)	0.27
Dividend Ex-Date	-	Current Ratio	7.68	EPS Y/Y TTM	-3.59%	Oper. Margin	-	RSI (14)	48.57	Volatility	9.72% 8.69%
Employees	59	Debt/Eq	0.57	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.10	Target Price	19.56
Option/Short	Yes / Yes	LT Debt/Eq	0.51	EPS Q/Q	-32.48%	Payout	-	Rel Volume	5.48	Prev Close	2.96
Sales Surprise	-	EPS Surprise	10.43%	Sales Q/Q	-	Earnings	Nov 05 BMO	Avg Volume	422.49K	Price	3.14
SMA20	11.90%	SMA50	-20.77%	SMA200	-35.57%	Trades		Volume	770,073	Change	6.25%

Date	Action	Analyst	Rating Change	Price Target Change
Today	Initiated	Raymond James	Outperform	$26
Sep-12-24	Initiated	Stifel	Buy	$16
Aug-13-24	Resumed	Jefferies	Buy	$16 → $17
May-30-24	Initiated	Wells Fargo	Overweight	$14
Mar-23-23	Upgrade	Jefferies	Hold → Buy	$4.50 → $6
May-26-22	Initiated	Jefferies	Hold	$5
Feb-07-22	Initiated	H.C. Wainwright	Buy	$33
Nov-29-21	Initiated	Needham	Buy	$23
Aug-18-20	Initiated	Wedbush	Outperform	$35
Aug-18-20	Initiated	Piper Sandler	Overweight	$40
Aug-18-20	Initiated	Cowen	Outperform
Aug-18-20	Initiated	BofA Securities	Buy	$33

Show Previous Ratings

Nov-27-24 08:30AM	Inozyme Pharma to Participate in the Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire)
Nov-13-24 09:35AM	Here's Why Inozyme Pharma (INZY) is Poised for a Turnaround After Losing -29.98% in 4 Weeks (Zacks) -5.59%
Nov-11-24 08:30AM	Inozyme Pharma to Present at Upcoming Investor Conferences (GlobeNewswire)
Nov-05-24 08:30AM	Inozyme Pharma Reports Third Quarter 2024 Financial Results and Provides Business Highlights (GlobeNewswire) -7.92%
Oct-24-24 01:15PM	Inozyme Pharma Announces Positive Interim Data from Phase 1 SEAPORT 1 Trial of INZ-701 (GlobeNewswire)
08:30AM	Loading…
Oct-17-24 08:30AM	Inozyme Pharma Announces Presentation of Interim Data from Phase 1 SEAPORT 1 Trial at the Upcoming American Society of Nephrology (ASN) Kidney Week 2024 (GlobeNewswire)
Oct-07-24 08:30AM	Inozyme Pharma Announces Appointment of Biopharmaceutical Commercial Leader Erik Harris to its Board of Directors (GlobeNewswire)
Sep-26-24 08:00AM	Inozyme Pharma Presents New Data at the American Society for Bone and Mineral Research (ASBMR) 2024 Annual Meeting (GlobeNewswire)
Aug-29-24 08:30AM	Inozyme Pharma to Participate at the 2024 Wells Fargo Healthcare Conference (GlobeNewswire)
Aug-18-24 09:03AM	Jefferies Predicts up to 270% Rally for These 2 Strong Buy Stocks (TipRanks)
Aug-06-24 01:52PM	INZY Stock Earnings: Inozyme Pharma Misses EPS for Q2 2024 (InvestorPlace)
08:30AM	Inozyme Pharma Reports Second Quarter 2024 Financial Results and Provides Business Highlights (GlobeNewswire)
Jul-25-24 08:30AM	Inozyme Pharma Publishes Preclinical Data Supporting INZ-701 as a Potential Therapy for a Broad Range of Serious Rare Diseases Impacting Bone Health and Blood Vessel Function (GlobeNewswire)
Jul-02-24 08:30AM	Inozyme Pharma Announces FDA Fast Track Designation for INZ-701 in ABCC6 Deficiency (GlobeNewswire)
Jun-29-24 08:37PM	Why Did Inozyme Pharma, Inc. (INZY) Get a Strong Buy Rating from Analysts? (Insider Monkey)
06:30PM	Loading…
06:30PM	10 Best Biotech Penny Stocks to Buy Now (Insider Monkey)
Jun-21-24 01:00PM	Inozyme Pharma Announces Presentation and Sponsored Symposium at the 11th International Conference on Children's Bone Health (ICCBH) (GlobeNewswire)
May-30-24 08:30AM	Inozyme Pharma to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-23-24 08:30AM	Inozyme Pharma to Present Recently Announced Data from Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE) at Upcoming Medical Conferences (GlobeNewswire)
May-08-24 08:30AM	Inozyme Pharma to Participate at the Bank of America Securities 2024 Health Care Conference (GlobeNewswire)
May-07-24 01:52PM	INZY Stock Earnings: Inozyme Pharma Misses EPS for Q1 2024 (InvestorPlace) -5.74%
08:30AM	Inozyme Pharma Reports First Quarter 2024 Financial Results and Provides Business Highlights (GlobeNewswire)
May-03-24 08:30AM	Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-08-24 06:30AM	Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency (GlobeNewswire) -8.42%
Apr-05-24 06:00PM	Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-02-24 08:30AM	Inozyme Pharma to Participate at the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire) -5.20%
Mar-26-24 08:30AM	Inozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024 (GlobeNewswire) +8.83%
Mar-12-24 08:30AM	Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights (GlobeNewswire)
Feb-26-24 08:30AM	Inozyme Pharma to Participate in the TD Cowen 44th Annual Health Care Conference (GlobeNewswire) +7.01%
Feb-06-24 08:30AM	Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:30AM	Loading…
Dec-05-23 08:30AM	Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-09-23 08:30AM	Inozyme Pharma to Participate in Upcoming Investor Conferences (GlobeNewswire) -5.81%
Nov-07-23 08:30AM	Inozyme Pharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights (GlobeNewswire) +7.02%
Nov-03-23 04:15PM	Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.80% -5.97%
Oct-26-23 08:30AM	Inozyme Pharma Announces Presentation at the American Society of Nephrology (ASN) Kidney Week 2023 (GlobeNewswire)
Oct-14-23 12:07PM	10 Stocks With Huge Catalysts on the Way (Insider Monkey)
Oct-10-23 12:00PM	Inozyme Pharma, Inc. (INZY) Moves to Buy: Rationale Behind the Upgrade (Zacks)
08:30AM	Inozyme Pharma Highlights Inclusion of Generalized Arterial Calcification of Infancy (GACI) in Genomics England's Generation Study of Rare Conditions (GlobeNewswire)
Oct-06-23 08:30AM	Inozyme Pharma Announces Three Poster Presentations at the American Society for Bone and Mineral Research (ASBMR) 2023 Annual Meeting (GlobeNewswire)
Sep-26-23 07:30AM	Inozyme Pharma Announces Positive Interim Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE) (GlobeNewswire)
Sep-20-23 08:30AM	Inozyme Pharma to Host Virtual Investor and Analyst Event on Sep. 26, 2023 (GlobeNewswire) +12.64%
Sep-06-23 08:30AM	Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-05-23 08:30AM	Inozyme Pharma to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-08-23 08:30AM	Inozyme Pharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights (GlobeNewswire)
Aug-07-23 10:50AM	Insiders Pour Millions Into These 2 Stocks Under $10 Heres Why Wall Street Thinks They Could Double (or More) (TipRanks)
Aug-03-23 04:01PM	Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.02%
Aug-01-23 04:01PM	Inozyme Pharma, Inc. Announces Closing of Public Offering of Common Stock (GlobeNewswire) -5.38%
Jul-27-23 11:20PM	Inozyme Pharma, Inc. Announces Pricing of Public Offering of Common Stock (GlobeNewswire) -6.09% -5.03%
04:33PM	Inozyme Pharma, Inc. Announces Proposed Offering of Common Stock (GlobeNewswire)
Jul-26-23 07:30AM	Inozyme Pharma Announces Updates on Global Development Strategy of INZ-701 for the Treatment of ENPP1 Deficiency (GlobeNewswire) -10.86%
Jul-19-23 08:30AM	Inozyme Pharma to Provide ENPP1 Deficiency Program Update on July 26, 2023 (GlobeNewswire) +8.67%
Jul-14-23 08:34AM	private equity firms who own 39% along with institutions invested in Inozyme Pharma, Inc. (NASDAQ:INZY) saw increase in their holdings value last week (Simply Wall St.)
Jun-27-23 08:30AM	Inozyme Pharma Announces Dosing of First Infant with ENPP1 Deficiency in a Phase 1b Trial of INZ-701 (GlobeNewswire)
Jun-15-23 12:53PM	We're Upping Our Price Targets on This Small-Cap Biotech Stock (TheStreet.com)
Jun-02-23 07:30AM	Inozyme Pharma to Present at the Jefferies Healthcare Conference (GlobeNewswire)
May-09-23 08:30AM	Inozyme Pharma Reports First Quarter 2023 Financial Results and Provides Business Highlights (GlobeNewswire) +9.53%
May-03-23 08:30AM	Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-16-23 09:01AM	A number of insiders bought Inozyme Pharma, Inc. (NASDAQ:INZY) stock last year, which is great news for shareholders (Simply Wall St.)
Apr-14-23 08:30AM	Inozyme Pharma to Present Recently Announced Preliminary Data from Ongoing Phase 1/2 Trial in ENPP1 Deficiency at the European Calcified Tissue Society Congress (ECTS) (GlobeNewswire)
Apr-11-23 08:30AM	Inozyme Pharma to Participate at the 22nd Annual Needham Virtual Healthcare Conference (GlobeNewswire) +8.27%
Apr-04-23 08:30AM	Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Operations Officer (GlobeNewswire)
Mar-28-23 09:04AM	Here's Why Inozyme Pharma Has My Attention (TheStreet.com) +18.11%
Mar-22-23 08:30AM	Inozyme Pharma Reports Full Year 2022 Financial Results and Provides Business Highlights (GlobeNewswire)
Mar-16-23 08:50AM	Why Earnings Season Could Be Great for Inozyme (INZY) (Zacks)
Mar-01-23 08:30AM	Inozyme Pharma to Participate in the Cowen 43rd Annual Health Care Conference (GlobeNewswire) +7.42%
Feb-16-23 08:59AM	Why Inozyme Pharma (INZY) Shares Are Trading Higher Today (Benzinga) +21.62%
07:30AM	Inozyme Pharma Reports Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 (GlobeNewswire)
Feb-06-23 07:30AM	Inozyme Pharma to Host Virtual Investor and Analyst Event on Feb. 16, 2023 (GlobeNewswire)
Feb-04-23 07:04AM	Institutions profited after Inozyme Pharma, Inc.'s (NASDAQ:INZY) market cap rose US$19m last week butprivate equity firms profited the most (Simply Wall St.)
Jan-09-23 08:30AM	Inozyme Pharma Announces Investor and Analyst Event and Highlights 2022 Progress (GlobeNewswire) -9.68%
Dec-05-22 08:30AM	Inozyme Pharma Announces Peer-Reviewed Publication Revealing Increased Prevalence of ENPP1 Deficiency (GlobeNewswire)
Dec-01-22 07:30AM	Inozyme Pharma to Participate at the BofA Securities Biotech SMID Cap Conference (GlobeNewswire)
Nov-10-22 08:30AM	Inozyme Pharma Reports Third Quarter 2022 Financial Results and Provides Business Updates (GlobeNewswire)
Nov-07-22 07:30AM	Inozyme Pharma to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-06-22 09:37AM	Inozyme Pharma, Inc.'s (NASDAQ:INZY) recent US$11m market cap decline means a loss of US$268k for insiders who bought this year (Simply Wall St.)
Nov-03-22 07:30AM	Inozyme Pharma Announces First Self-Administration of INZ-701 in Ongoing ENPP1 Deficiency Phase 1/2 Clinical Trial (GlobeNewswire) +5.92%
Oct-31-22 07:30AM	Inozyme Pharma Announces Publication of Comprehensive ENPP1 Variant Database (GlobeNewswire)
Sep-26-22 06:17AM	We're Keeping An Eye On Inozyme Pharma's (NASDAQ:INZY) Cash Burn Rate (Simply Wall St.)
Sep-06-22 07:30AM	Inozyme Pharma to Present at H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-24-22 12:24PM	Sorrento (SRNE) Up on Positive Result From Lung Cancer Study (Zacks) +5.20%
Aug-23-22 12:42PM	bluebird (BLUE) Up 101% in the Past Three Months: Here's Why (Zacks)
Aug-18-22 11:00AM	bluebird's (BLUE) Gene Therapy Gets FDA Nod for Beta-Thalassemia (Zacks)
Aug-17-22 12:27PM	Artelo's (ARTL) FABP5 Inhibitor Effective in Pre-Clinical Study (Zacks)
Aug-15-22 07:30AM	Inozyme Pharma Reports Second Quarter 2022 Financial Results and Provides Business Updates (GlobeNewswire) +8.05%
Aug-12-22 11:39AM	Aptinyx's (APTX) Mid-Stage Fibromyalgia Study Fails to Meet Goal (Zacks)
Jul-26-22 07:30AM	Inozyme Pharma Secures Flexible Debt Facility for up to $70 Million with K2 HealthVentures (GlobeNewswire) -6.41%
Jul-20-22 10:56AM	Inozyme Pharma Post Encouraging Early Data From Genetic Disorder Trial (Benzinga) -16.88%
Jul-19-22 04:30PM	Inozyme Pharma Announces Positive Preliminary Data from Phase 1/2 Clinical Trial of INZ-701 in Subjects with ABCC6 Deficiency (pseudoxanthoma elasticum or PXE) (GlobeNewswire)
Jun-24-22 09:55AM	How Much Upside is Left in Inozyme Pharma, Inc. (INZY)? Wall Street Analysts Think 309% (Zacks)
Jun-16-22 07:30AM	Inozyme Pharma Announces Partnership with Rady Childrens Institute for Genomic Medicine to Advance Newborn Screening for Genetic Diseases (GlobeNewswire)
Jun-07-22 07:30AM	Inozyme Pharma Appoints Kurt Gunter, M.D., as Chief Medical Officer (GlobeNewswire) +10.03%
Jun-01-22 07:30AM	Inozyme Pharma to Present at the 2022 Jefferies Healthcare Conference (GlobeNewswire) -12.20%
May-28-22 08:07AM	Is Inozyme Pharma, Inc. (NASDAQ:INZY) Popular Amongst Institutions? (Simply Wall St.)
May-10-22 07:30AM	Inozyme Pharma Reports First Quarter 2022 Financial Results and Provides Business Highlights (GlobeNewswire) +10.30%
May-06-22 05:30PM	MiMedx Group and Inozyme Stock See Action From Activist Investors (Barrons.com)
May-03-22 07:30AM	Inozyme Pharma to Present at Upcoming Investor Conferences (GlobeNewswire)
Apr-28-22 06:39AM	Co-Founder Axel Bolte Just Bought 36% More Shares In Inozyme Pharma, Inc. (NASDAQ:INZY) (Simply Wall St.)
Apr-25-22 09:23PM	3 Strong Buy Stocks Sparking Interest From Insiders (TipRanks) -10.74%
Apr-18-22 12:32PM	Companies Like Inozyme Pharma (NASDAQ:INZY) Are In A Position To Invest In Growth (Simply Wall St.)
Apr-14-22 08:16AM	Inozyme Pharma Announces $73 Million Underwritten Offering Priced At-the-Market (GlobeNewswire) +15.45%

Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company. It engages in the business of developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company was founded by Axel Bolte, Joseph P. Schlessinger, and Demetrios T. Braddock in September 2015 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Treco Douglas A	CEO	Apr 02 '24	Sale	6.94	7,523	52,210	20,665	Apr 03 05:23 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

INZY

Inozyme Pharma Inc

Upgrade your FINVIZ experience